Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Micah Chan

Nephrology Fitchburg, WI Medical Doctor

NPI 1659322048 CMS profile 119790

3034 Fish Hatchery Rd Ste B, Uw Nephrology, Fitchburg, WI 53713

Open in the dashboard

General payments

$80,338

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$142,876 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Micah Chan of Fitchburg, WI is reported in the CMS Open Payments database as having received $80,338 across 162 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $142,876 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,545 14
2024 General $7,977 18
2023 General $19,231 38
2022 General $19,573 40
2021 General $5,476 18
2020 General $14,432 13
2019 General $7,104 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Micah Chan
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Micah Chan were reported at $6,545. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Micah Chan Nephrology median Middle half National median
2019 $7,104 $236 $90–$588 $163
2020 $14,432 $135 $46–$364 $114
2021 $5,476 $202 $67–$551 $132
2022 $19,573 $242 $77–$695 $149
2023 $19,231 $254 $84–$766 $160
2024 $7,977 $300 $99–$852 $164
2025 $6,545 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $44,800 74 payments
  2. Bard Peripheral Vascular, Inc. $11,382 21 payments
  3. Mozarc Medical US LLC $10,196 41 payments
  4. Covidien LP $6,124 11 payments
  5. Phraxis, Inc. $5,200 3 payments
  6. Argon Medical Devices, Inc. $1,662 4 payments
  7. Penumbra, Inc. $625 4 payments
  8. VentureMed Group, Inc. $133 1 payment
  9. AV Medical Technologies Ltd. $120 1 payment
  10. Medtronic Vascular, Inc. $85 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $34,593 18 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,900 10 payments
  3. Travel and Lodging $16,067 55 payments
  4. Food and Beverage $6,767 78 payments
  5. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Argyle Dialysis Catheters $35,073 47 payments
  2. ARGYLE Dialysis Catheters $9,748 37 payments
  3. ELLIPSYS VASCULAR ACCESS SYSTEM $6,585 4 payments
  4. WavelinQ $2,686 2 payments
  5. Argyle Dialysis Catheters $2,400 2 payments
  6. IN.PACT AV $1,600 2 payments
  7. Clot Management $1,519 3 payments
  8. Venous InterGraft $1,200 1 payment
  9. Argyle Dialysis/Vascular Access $1,200 1 payment
  10. TurboHawk $1,182 17 payments
  11. Other $2,540 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

217

Median for Nephrology: 954

Drug cost

$1,781

Median for Nephrology: $127,050

Branded share of claims

0%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calcitriol Generic 74 $717
Hydralazine Hcl Generic 47 $386
Carvedilol Generic 19 $174
Losartan Potassium Generic 23 $169
Lisinopril Generic 19 $160
Amlodipine Besylate Generic 20 $143
Furosemide Generic 15 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$38,576

Medicare's payments for the services billed

Medicare patients

236

Average age 69

Services billed

702

105 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 56%
Heart failure 52%
Ischemic heart disease 50%
Depression 35%
Arthritis 33%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record